Holen Sie sich die Stockscreener-App
143.93
0.83%
-1.21
Vorhandelsmarkt:
143.57
-0.36
-0.25%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Is Gilead Sciences Inc. stock overvalued by current metricsWeekly Trade Review & Low Drawdown Momentum Trade Ideas - Naître et grandir
These 3 Cash Flow Machines Provide Stability in Uncertain Markets - Investing.com
BofA reiterates Gilead Sciences stock Buy rating on Yeztugo uptake - Investing.com
Gilead, South Africa in talks for HIV drug production (GILD) - Seeking Alpha
Gilead Sciences, Inc. $GILD Stock Position Lifted by Orion Porfolio Solutions LLC - MarketBeat
Kingsview Wealth Management LLC Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Edgar Lomax Co. VA Has $19.46 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Fisher Asset Management LLC - MarketBeat
South Africa seeks local production of Gilead’s HIV prevention drug - WHTC
Gilead and South Africa are negotiating a license for local production of new HIV drug - statnews.com
Stonebridge Capital Advisors LLC Sells 9,029 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - Yahoo Finance
South Dakota Investment Council Cuts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Picton Mahoney Asset Management Boosts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences stock forecast for 2030: Can $7.8B Arcellx deal push GILD to $220 with no patent cliff until 2036? - Traders Union
Crossmark Global Holdings Inc. Grows Stake in Gilead Sciences, Inc. $GILD - MarketBeat
South Africa seeks local production of Gilead's HIV prevention drug - marketscreener.com
Let me see you One2PrEP: Gilead campaign targets stigma with pop culture punch - Medical Marketing and Media
Griffith & Werner Inc. Makes New $1.77 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Dimensional Fund Advisors LP Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Multiple Myeloma Market 2026: Gilead Sciences Acquires Arcellx for $7.8B to Control CAR-T Therapy - openPR.com
Gilead Sciences, Inc. $GILD Shares Sold by CI Investments Inc. - MarketBeat
Gilead Sciences Stock To $192? - Trefis
How Does Gilead Sciences Stock Stack Up Against Its Peers? - Trefis
Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead Sciences’ Yeztugo Revenue Is Set to Jump 400%: Here’s What Comes Next - TIKR.com
Gilead at TD Cowen Conference: Strategic Growth and Expansion - Investing.com
Teachers Retirement System of The State of Kentucky Sells 18,145 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Victory Capital Management Inc. Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Navigates Market Shifts Within The Nasdaq Composite - Kalkine Media
Gilead Sciences (NASDAQ:GILD) Stock Acquired Rep. Josh Gottheimer - MarketBeat
Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance - Yahoo Finance
Gilead Sciences to Present at Upcoming Investor Conference - Business Wire
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead Sciences Insider Sold Shares Worth $1,447,859, According to a Recent SEC Filing - marketscreener.com
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention I - PharmiWeb.com
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term - Nasdaq
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia - Business Wire
Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S - TradingView
Gilead Sciences, Inc. $GILD Shares Sold by APG Asset Management N.V. - MarketBeat
Assessing Gilead Sciences (GILD) Valuation As Recent Share Price Momentum Meets Conflicting Fair Value Signals - Yahoo Finance
Gilead Sciences, Inc. $GILD Holdings Cut by Rafferty Asset Management LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by DNB Asset Management AS - MarketBeat
Argent Trust Co Buys 21,785 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Josh Gottheimer makes key trades in Gilead Sciences and Intercontinental Exchange By Investing.com - Investing.com South Africa
Josh Gottheimer makes key trades in Gilead Sciences and Intercontinental Exchange - Investing.com
The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease - CSRwire
P/E Ratio Insights for Gilead Sciences - Benzinga
Gilead Sciences Inc Stock Moved Up by 3.72% on Feb 27: What Investors Need To Know - TradingKey
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector? - Barchart.com
Handelsbanken Fonder AB Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Q3 EPS Estimates for Gilead Sciences Cut by Zacks Research - MarketBeat
MAI Capital Management Purchases 13,649 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Erste Asset Management GmbH Sells 30,299 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Clifford Swan Investment Counsel LLC Trims Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation Grants County College of Morris Foundation $150,000 Towards New Center for Health Professions Building - TAPinto
Gilead Sciences Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $161.00 - MarketBeat
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data - BioSpace
Mitsubishi UFJ Asset Management Co. Ltd. Has $287.48 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Intech Investment Management LLC Raises Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Q1 EPS Forecast Lifted by Zacks Research - MarketBeat
Fox Run Management L.L.C. Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy - BioSpace
This biotech stock is having its best day ever. Gilead Sciences is buying it. - MSN
Gilead Sciences (GILD) HIV Pill Shows Promising Results in Phase 3 Trials - GuruFocus
Gilead reports positive phase 3 data for HIV treatment combo - Investing.com
Gilead's BIC/LEN Pill Maintains Viral Suppression in HIV Trials - Intellectia AI
Gilead (GILD) Introduces Promising HIV Treatment in Phase 3 Tria - GuruFocus
1.25%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):